Experimental in vitro, ex vivo and in vivo models in prostate cancer research.
Journal
Nature reviews. Urology
ISSN: 1759-4820
Titre abrégé: Nat Rev Urol
Pays: England
ID NLM: 101500082
Informations de publication
Date de publication:
03 2023
03 2023
Historique:
accepted:
25
10
2022
pubmed:
1
12
2022
medline:
9
3
2023
entrez:
30
11
2022
Statut:
ppublish
Résumé
Androgen deprivation therapy has a central role in the treatment of advanced prostate cancer, often causing initial tumour remission before increasing independence from signal transduction mechanisms of the androgen receptor and then eventual disease progression. Novel treatment approaches are urgently needed, but only a fraction of promising drug candidates from the laboratory will eventually reach clinical approval, highlighting the demand for critical assessment of current preclinical models. Such models include standard, genetically modified and patient-derived cell lines, spheroid and organoid culture models, scaffold and hydrogel cultures, tissue slices, tumour xenograft models, patient-derived xenograft and circulating tumour cell eXplant models as well as transgenic and knockout mouse models. These models need to account for inter-patient and intra-patient heterogeneity, the acquisition of primary or secondary resistance, the interaction of tumour cells with their microenvironment, which make crucial contributions to tumour progression and resistance, as well as the effects of the 3D tissue network on drug penetration, bioavailability and efficacy.
Identifiants
pubmed: 36451039
doi: 10.1038/s41585-022-00677-z
pii: 10.1038/s41585-022-00677-z
doi:
Substances chimiques
Androgen Antagonists
0
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
158-178Informations de copyright
© 2022. Springer Nature Limited.
Références
Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2020. CA Cancer J. Clin. 70, 7–30 (2020).
doi: 10.3322/caac.21590
pubmed: 31912902
Rebello, R. J. et al. Prostate cancer. Nat. Rev. Dis. Primers 7, 9 (2021).
pubmed: 33542230
doi: 10.1038/s41572-020-00243-0
Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2018. CA Cancer J. Clin. 68, 7–30 (2018).
pubmed: 29313949
doi: 10.3322/caac.21442
Yamada, Y. & Beltran, H. The treatment landscape of metastatic prostate cancer. Cancer Lett. 519, 20–29 (2021).
pubmed: 34153403
pmcid: 8403655
doi: 10.1016/j.canlet.2021.06.010
Antonarakis, E. S., Gomella, L. G. & Petrylak, D. P. When and how to use PARP inhibitors in prostate cancer: a systematic review of the literature with an update on on-going trials. Eur. Urol. Oncol. 3, 594–611 (2020).
pubmed: 32814685
doi: 10.1016/j.euo.2020.07.005
Sartor, O. et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N. Engl. J. Med. 385, 1091–1103 (2021).
pubmed: 34161051
pmcid: 8446332
doi: 10.1056/NEJMoa2107322
Litwin, M. S. & Tan, H. J. The diagnosis and treatment of prostate cancer: a review. JAMA 317, 2532–2542 (2017).
pubmed: 28655021
doi: 10.1001/jama.2017.7248
Ali, A. et al. Prostate zones and cancer: lost in transition? Nat. Rev. Urol. 19, 101–115 (2022).
pubmed: 34667303
doi: 10.1038/s41585-021-00524-7
Kumar, A. et al. Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer. Nat. Med. 22, 369–378 (2016).
pubmed: 26928463
pmcid: 5045679
doi: 10.1038/nm.4053
Cancer Genome Atlas Research Network. The molecular taxonomy of primary prostate cancer. Cell 163, 1011–1025 (2015).
doi: 10.1016/j.cell.2015.10.025
Tomlins, S. A. et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310, 644–648 (2005).
pubmed: 16254181
doi: 10.1126/science.1117679
Clark, J. et al. Complex patterns of ETS gene alteration arise during cancer development in the human prostate. Oncogene 27, 1993–2003 (2008).
pubmed: 17922029
doi: 10.1038/sj.onc.1210843
Clark, J. P. & Cooper, C. S. ETS gene fusions in prostate cancer. Nat. Rev. Urol. 6, 429–439 (2009).
pubmed: 19657377
doi: 10.1038/nrurol.2009.127
Espiritu, S. M. G. et al. The evolutionary landscape of localized prostate cancers drives clinical aggression. Cell 173, 1003–1013.e1015 (2018).
pubmed: 29681457
doi: 10.1016/j.cell.2018.03.029
Salami, S. S. et al. Transcriptomic heterogeneity in multifocal prostate cancer. JCI Insight 3, e123468 (2018).
pubmed: 30385730
pmcid: 6238741
doi: 10.1172/jci.insight.123468
Falzarano, S. M. et al. ERG rearrangement is present in a subset of transition zone prostatic tumors. Mod. Pathol. 23, 1499–1506 (2010).
pubmed: 20693982
doi: 10.1038/modpathol.2010.150
Varma, M., Shah, R. B., Williamson, S. R. & Berney, D. M. 2019 Gleason grading recommendations from ISUP and GUPS: broadly concordant but with significant differences. Virchows Arch. 478, 813–815 (2021).
pubmed: 33392799
doi: 10.1007/s00428-020-03003-3
Rubin, M. A., Girelli, G. & Demichelis, F. Genomic correlates to the newly proposed grading prognostic groups for prostate cancer. Eur. Urol. 69, 557–560 (2016).
pubmed: 26563871
doi: 10.1016/j.eururo.2015.10.040
Wilkinson, S. et al. Nascent prostate cancer heterogeneity drives evolution and resistance to intense hormonal therapy. Eur. Urol. 80, 746–757 (2021).
pubmed: 33785256
pmcid: 8473585
doi: 10.1016/j.eururo.2021.03.009
Aggarwal, R. et al. Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: a multi-institutional prospective study. J. Clin. Oncol. 36, 2492–2503 (2018).
pubmed: 29985747
pmcid: 6366813
doi: 10.1200/JCO.2017.77.6880
Robinson, D. et al. Integrative clinical genomics of advanced prostate cancer. Cell 161, 1215–1228 (2015).
pubmed: 26000489
pmcid: 4484602
doi: 10.1016/j.cell.2015.05.001
Binnewies, M. et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat. Med. 24, 541–550 (2018).
pubmed: 29686425
pmcid: 5998822
doi: 10.1038/s41591-018-0014-x
Hofbauer, L. C. et al. Novel approaches to target the microenvironment of bone metastasis. Nat. Rev. Clin. Oncol. 18, 488–505 (2021).
pubmed: 33875860
doi: 10.1038/s41571-021-00499-9
Garon, E. B. et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N. Engl. J. Med. 372, 2018–2028 (2015).
pubmed: 25891174
doi: 10.1056/NEJMoa1501824
Robert, C. et al. Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med. 372, 2521–2532 (2015).
pubmed: 25891173
doi: 10.1056/NEJMoa1503093
Abida, W. et al. Analysis of the prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade. JAMA Oncol. 5, 471–478 (2019).
pubmed: 30589920
doi: 10.1001/jamaoncol.2018.5801
van Bokhoven, A. et al. Molecular characterization of human prostate carcinoma cell lines. Prostate 57, 205–225 (2003).
pubmed: 14518029
doi: 10.1002/pros.10290
Russell, P. J. & Kingsley, E. A. Human prostate cancer cell lines. Methods Mol. Med. 81, 21–39 (2003).
pubmed: 12725112
van Weerden, W. M., Bangma, C. & de Wit, R. Human xenograft models as useful tools to assess the potential of novel therapeutics in prostate cancer. Br. J. Cancer 100, 13–18 (2009).
pubmed: 19088719
doi: 10.1038/sj.bjc.6604822
Namekawa, T., Ikeda, K., Horie-Inoue, K. & Inoue, S. Application of prostate cancer models for preclinical study: advantages and limitations of cell lines, patient-derived xenografts, and three-dimensional culture of patient-derived cells. Cells 8, 74 (2019).
pubmed: 30669516
pmcid: 6357050
doi: 10.3390/cells8010074
Nguyen, H. M. et al. LuCaP prostate cancer patient-derived xenografts reflect the molecular heterogeneity of advanced disease and serve as models for evaluating cancer therapeutics. Prostate 77, 654–671 (2017).
pubmed: 28156002
pmcid: 5354949
doi: 10.1002/pros.23313
Young, S. R. et al. Establishment and serial passage of cell cultures derived from LuCaP xenografts. Prostate 73, 1251–1262 (2013).
pubmed: 23740600
pmcid: 3720815
doi: 10.1002/pros.22610
Stone, K. R., Mickey, D. D., Wunderli, H., Mickey, G. H. & Paulson, D. F. Isolation of a human prostate carcinoma cell line (DU 145). Int. J. Cancer 21, 274–281 (1978).
pubmed: 631930
doi: 10.1002/ijc.2910210305
Kaighn, M. E., Narayan, K. S., Ohnuki, Y., Lechner, J. F. & Jones, L. W. Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest. Urol. 17, 16–23 (1979).
pubmed: 447482
Horoszewicz, J. S. et al. The LNCaP cell line–a new model for studies on human prostatic carcinoma. Prog. Clin. Biol. Res. 37, 115–132 (1980).
pubmed: 7384082
van Bokhoven, A., Varella-Garcia, M., Korch, C., Hessels, D. & Miller, G. J. Widely used prostate carcinoma cell lines share common origins. Prostate 47, 36–51 (2001).
pubmed: 11304728
doi: 10.1002/pros.1045
van Bokhoven, A., Varella-Garcia, M., Korch, C. & Miller, G. J. TSU-Pr1 and JCA-1 cells are derivatives of T24 bladder carcinoma cells and are not of prostatic origin. Cancer Res. 61, 6340–6344 (2001).
pubmed: 11522622
Rubin, M. A. et al. Rapid (“warm”) autopsy study for procurement of metastatic prostate cancer. Clin. Cancer Res. 6, 1038–1045 (2000).
pubmed: 10741732
Lee, Y. G. et al. Establishment and characterization of a new human prostatic cancer cell line: DuCaP. Vivo 15, 157–162 (2001).
Korenchuk, S. et al. VCaP, a cell-based model system of human prostate cancer. Vivo 15, 163–168 (2001).
Sfanos, K. S. et al. Identification of replication competent murine gammaretroviruses in commonly used prostate cancer cell lines. PLoS ONE 6, e20874 (2011).
pubmed: 21698104
pmcid: 3117837
doi: 10.1371/journal.pone.0020874
Griffiths, J. C. The laboratory diagnosis of prostatic adenocarcinoma. Crit. Rev. Clin. Lab. Sci. 19, 187–204 (1983).
pubmed: 6144453
doi: 10.3109/10408368309165763
Moch, H., Humphrey, P. A., Ulbright, T. M. & Reuter, V. WHO Classification of Tumours of the Urinary System and Male Genital Organs. (International Agency for Research on Cancer, 2016).
Merkens, L. et al. Aggressive variants of prostate cancer: underlying mechanisms of neuroendocrine transdifferentiation. J. Exp. Clin. Cancer Res. 41, 46 (2022).
pubmed: 35109899
pmcid: 8808994
doi: 10.1186/s13046-022-02255-y
Grossman, H. B., Wedemeyer, G., Ren, L. & Carey, T. E. UM-SCP-1, a new human cell line derived from a prostatic squamous cell carcinoma. Cancer Res. 44, 4111–4117 (1984).
pubmed: 6378378
Kim, C. J., Kushima, R., Okada, Y. & Seto, A. Establishment and characterization of a prostatic small-cell carcinoma cell line (PSK-1) derived from a patient with Klinefelter syndrome. Prostate 42, 287–294 (2000).
pubmed: 10679758
doi: 10.1002/(SICI)1097-0045(20000301)42:4<287::AID-PROS6>3.0.CO;2-F
Okasho, K. et al. Establishment and characterization of a novel treatment-related neuroendocrine prostate cancer cell line KUCaP13. Cancer Sci. 112, 2781–2791 (2021).
pubmed: 33960594
pmcid: 8253279
doi: 10.1111/cas.14935
Steinestel, J. et al. Detecting predictive androgen receptor modifications in circulating prostate cancer cells. Oncotarget 10, 4213–4223 (2019).
pubmed: 31289619
doi: 10.18632/oncotarget.3925
Jividen, K. et al. Genomic analysis of DNA repair genes and androgen signaling in prostate cancer. BMC Cancer 18, 960 (2018).
pubmed: 30305041
pmcid: 6180441
doi: 10.1186/s12885-018-4848-x
Cornford, P. et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: treatment of relapsing and metastatic prostate cancer. Eur. Urol. 79, 263–282 (2021).
pubmed: 33039206
doi: 10.1016/j.eururo.2020.09.046
Teroerde, M. et al. in Prostate Cancer [internet] (eds Bott, S. R. J. & Ng, K. L.) (Exon Publications, 2021).
Perryman, L. A. et al. Over-expression of p53 mutants in LNCaP cells alters tumor growth and angiogenesis in vivo. Biochem. Biophys. Res. Commun. 345, 1207–1214 (2006).
pubmed: 16723121
doi: 10.1016/j.bbrc.2006.05.020
Lee, J. K. et al. N-Myc drives neuroendocrine prostate cancer initiated from human prostate epithelial cells. Cancer Cell 29, 536–547 (2016).
pubmed: 27050099
pmcid: 4829466
doi: 10.1016/j.ccell.2016.03.001
Souza, A. G. et al. Comparative assay of 2D and 3D cell culture models: proliferation, gene expression and anticancer drug response. Curr. Pharm. Des. 24, 1689–1694 (2018).
pubmed: 29623827
doi: 10.2174/1381612824666180404152304
Sutherland, R. M. Cell and environment interactions in tumor microregions: the multicell spheroid model. Science 240, 177–184 (1988).
pubmed: 2451290
doi: 10.1126/science.2451290
Dietrichs, D. et al. Three-dimensional growth of prostate cancer cells exposed to simulated microgravity. Front. Cell Dev. Biol. 10, 841017 (2022).
pubmed: 35252204
pmcid: 8893349
doi: 10.3389/fcell.2022.841017
Grimm, D. et al. The fight against cancer by microgravity: the multicellular spheroid as a metastasis model. Int. J. Mol. Sci. 23, 3073 (2022).
pubmed: 35328492
pmcid: 8953941
doi: 10.3390/ijms23063073
Fontana, F. et al. Three-dimensional cell cultures as an in vitro tool for prostate cancer modeling and drug discovery. Int. J. Mol. Sci. 21, 6806 (2020).
pubmed: 32948069
pmcid: 7554845
doi: 10.3390/ijms21186806
Foty, R. A simple hanging drop cell culture protocol for generation of 3D spheroids. J. Vis. Exp. https://doi.org/10.3791/2720 (2011).
doi: 10.3791/2720
pubmed: 21587162
pmcid: 3197119
Hagemann, J. et al. Spheroid-based 3D cell cultures enable personalized therapy testing and drug discovery in head and neck cancer. Anticancer. Res. 37, 2201–2210 (2017).
pubmed: 28476783
doi: 10.21873/anticanres.11555
Halfter, K. et al. Prospective cohort study using the breast cancer spheroid model as a predictor for response to neoadjuvant therapy–the SpheroNEO study. BMC Cancer 15, 519 (2015).
pubmed: 26169261
pmcid: 4501185
doi: 10.1186/s12885-015-1491-7
Bray, L. J., Hutmacher, D. W. & Bock, N. Addressing patient specificity in the engineering of tumor models. Front. Bioeng. Biotechnol. 7, 217 (2019).
pubmed: 31572718
pmcid: 6751285
doi: 10.3389/fbioe.2019.00217
Gillet, J. P., Varma, S. & Gottesman, M. M. The clinical relevance of cancer cell lines. J. Natl Cancer Inst. 105, 452–458 (2013).
pubmed: 23434901
pmcid: 3691946
doi: 10.1093/jnci/djt007
Ingram, M. et al. Tissue engineered tumor models. Biotech. Histochem. 85, 213–229 (2010).
pubmed: 20482463
doi: 10.3109/10520295.2010.483655
Hsiao, A. Y. et al. Microfluidic system for formation of PC-3 prostate cancer co-culture spheroids. Biomaterials 30, 3020–3027 (2009).
pubmed: 19304321
pmcid: 2675053
doi: 10.1016/j.biomaterials.2009.02.047
Bansal, N. et al. BMI-1 Targeting interferes with patient-derived tumor-initiating cell survival and tumor growth in prostate cancer. Clin. Cancer Res. 22, 6176–6191 (2016).
pubmed: 27307599
pmcid: 5159329
doi: 10.1158/1078-0432.CCR-15-3107
Bansal, N. et al. Enrichment of human prostate cancer cells with tumor initiating properties in mouse and zebrafish xenografts by differential adhesion. Prostate 74, 187–200 (2014).
pubmed: 24154958
doi: 10.1002/pros.22740
Linxweiler, J. et al. Patient-derived, three-dimensional spheroid cultures provide a versatile translational model for the study of organ-confined prostate cancer. J. Cancer Res. Clin. Oncol. 145, 551–559 (2019).
pubmed: 30474758
doi: 10.1007/s00432-018-2803-5
Jouberton, E., Voissiere, A., Penault-Llorca, F., Cachin, F. & Miot-Noirault, E. Multicellular tumor spheroids of LNCaP-Luc prostate cancer cells as in vitro screening models for cytotoxic drugs. Am. J. Cancer Res. 12, 1116–1128 (2022).
pubmed: 35411223
pmcid: 8984876
Gao, D. et al. Organoid cultures derived from patients with advanced prostate cancer. Cell 159, 176–187 (2014).
pubmed: 25201530
pmcid: 4237931
doi: 10.1016/j.cell.2014.08.016
Cheaito, K. et al. Establishment and characterization of prostate organoids from treatment-naïve patients with prostate cancer. Oncol. Lett. 23, 6 (2022).
pubmed: 34820005
doi: 10.3892/ol.2021.13124
Drost, J. et al. Organoid culture systems for prostate epithelial and cancer tissue. Nat. Protoc. 11, 347–358 (2016).
pubmed: 26797458
pmcid: 4793718
doi: 10.1038/nprot.2016.006
Pauli, C. et al. Personalized in vitro and in vivo cancer models to guide precision medicine. Cancer Discov. 7, 462–477 (2017).
pubmed: 28331002
pmcid: 5413423
doi: 10.1158/2159-8290.CD-16-1154
Kamatar, A., Gunay, G. & Acar, H. Natural and synthetic biomaterials for engineering multicellular tumor spheroids. Polymers 12, 2506 (2020).
pubmed: 33126468
pmcid: 7692845
doi: 10.3390/polym12112506
Van Hemelryk, A. et al. Modeling prostate cancer treatment responses in the organoid era: 3D environment impacts drug testing. Biomolecules 11, 1572 (2021).
pubmed: 34827570
pmcid: 8615701
doi: 10.3390/biom11111572
Fong, E. L. et al. Hydrogel-based 3D model of patient-derived prostate xenograft tumors suitable for drug screening. Mol. Pharm. 11, 2040–2050 (2014).
pubmed: 24779589
pmcid: 4096229
doi: 10.1021/mp500085p
Bray, L. J. et al. Multi-parametric hydrogels support 3D in vitro bioengineered microenvironment models of tumour angiogenesis. Biomaterials 53, 609–620 (2015).
pubmed: 25890757
doi: 10.1016/j.biomaterials.2015.02.124
Furesi, G., Rauner, M. & Hofbauer, L. C. Emerging players in prostate cancer-bone Niche communication. Trends Cancer 7, 112–121 (2021).
pubmed: 33274720
doi: 10.1016/j.trecan.2020.09.006
Shokoohmand, A. et al. Microenvironment engineering of osteoblastic bone metastases reveals osteomimicry of patient-derived prostate cancer xenografts. Biomaterials 220, 119402 (2019).
pubmed: 31400612
doi: 10.1016/j.biomaterials.2019.119402
Bock, N. et al. Engineering osteoblastic metastases to delineate the adaptive response of androgen-deprived prostate cancer in the bone metastatic microenvironment. Bone Res. 7, 13 (2019).
pubmed: 31044095
pmcid: 6486620
doi: 10.1038/s41413-019-0049-8
Bock, N. et al. In vitro engineering of a bone metastases model allows for study of the effects of antiandrogen therapies in advanced prostate cancer. Sci. Adv. 7, eabg2564 (2021).
pubmed: 34193425
pmcid: 8245033
doi: 10.1126/sciadv.abg2564
Pereira, B. A. et al. Tissue engineered human prostate microtissues reveal key role of mast cell-derived tryptase in potentiating cancer-associated fibroblast (CAF)-induced morphometric transition in vitro. Biomaterials 197, 72–85 (2019).
pubmed: 30641266
doi: 10.1016/j.biomaterials.2018.12.030
Merz, L. et al. Tumor tissue slice cultures as a platform for analyzing tissue-penetration and biological activities of nanoparticles. Eur. J. Pharm. Biopharm. 112, 45–50 (2017).
pubmed: 27864052
doi: 10.1016/j.ejpb.2016.11.013
Perez, L. M. & Nonn, L. Harnessing the utility of ex vivo patient prostate tissue slice cultures. Front. Oncol. 12, 864723 (2022).
pubmed: 35433436
pmcid: 9008363
doi: 10.3389/fonc.2022.864723
Zhao, H. et al. Patient-derived tissue slice grafts accurately depict response of high-risk primary prostate cancer to androgen deprivation therapy. J. Transl. Med. 11, 199 (2013).
pubmed: 23985008
pmcid: 3766103
doi: 10.1186/1479-5876-11-199
Figiel, S. et al. Functional organotypic cultures of prostate tissues: a relevant preclinical model that preserves hypoxia sensitivity and calcium signaling. Am. J. Pathol. 189, 1268–1275 (2019).
pubmed: 30954471
doi: 10.1016/j.ajpath.2019.02.017
van de Merbel, A. F. et al. An ex vivo tissue culture model for the assessment of individualized drug responses in prostate and bladder cancer. Front. Oncol. 8, 400 (2018).
pubmed: 30333957
pmcid: 6176278
doi: 10.3389/fonc.2018.00400
Zhang, W. et al. Ex vivo treatment of prostate tumor tissue recapitulates in vivo therapy response. Prostate 79, 390–402 (2019).
pubmed: 30520109
doi: 10.1002/pros.23745
Gerlach, M. M. et al. Slice cultures from head and neck squamous cell carcinoma: a novel test system for drug susceptibility and mechanisms of resistance. Br. J. Cancer 110, 479–488 (2014).
pubmed: 24263061
doi: 10.1038/bjc.2013.700
Koerfer, J. et al. Organotypic slice cultures of human gastric and esophagogastric junction cancer. Cancer Med. 5, 1444–1453 (2016).
pubmed: 27073068
pmcid: 4944870
doi: 10.1002/cam4.720
Sonnichsen, R. et al. Individual susceptibility analysis using patient-derived slice cultures of colorectal carcinoma. Clin. Colorectal Cancer 17, e189–e199 (2018).
pubmed: 29233603
doi: 10.1016/j.clcc.2017.11.002
Merz, F. et al. Organotypic slice cultures of human glioblastoma reveal different susceptibilities to treatments. Neuro Oncol. 15, 670–681 (2013).
pubmed: 23576601
pmcid: 3661091
doi: 10.1093/neuonc/not003
Chakrabarty, S. et al. A microfluidic cancer-on-chip platform predicts drug response using organotypic tumor slice culture. Cancer Res. 82, 510–520 (2021).
pubmed: 34872965
pmcid: 9397621
doi: 10.1158/0008-5472.CAN-21-0799
Astolfi, M. et al. Micro-dissected tumor tissues on chip: an ex vivo method for drug testing and personalized therapy. Lab Chip 16, 312–325 (2016).
pubmed: 26659477
doi: 10.1039/C5LC01108F
Dorrigiv, D. et al. Microdissected tissue vs tissue slices-a comparative study of tumor explant models cultured on-chip and off-chip. Cancers 13, 4208 (2021).
pubmed: 34439362
pmcid: 8394960
doi: 10.3390/cancers13164208
Kashaninejad, N. et al. Organ-tumor-on-a-chip for chemosensitivity assay: a critical review. Micromachines 7, 130 (2016).
pubmed: 30404302
pmcid: 6190381
doi: 10.3390/mi7080130
Pandya, H. J. et al. A microfluidic platform for drug screening in a 3D cancer microenvironment. Biosens. Bioelectron. 94, 632–642 (2017).
pubmed: 28371753
pmcid: 5499155
doi: 10.1016/j.bios.2017.03.054
Kunzi-Rapp, K. et al. Chorioallantoic membrane assay: vascularized 3-dimensional cell culture system for human prostate cancer cells as an animal substitute model. J. Urol. 166, 1502–1507 (2001).
pubmed: 11547121
doi: 10.1016/S0022-5347(05)65820-X
Wu, X., Gong, S., Roy-Burman, P., Lee, P. & Culig, Z. Current mouse and cell models in prostate cancer research. Endocr. Relat. Cancer 20, R155–R170 (2013).
pubmed: 23580590
doi: 10.1530/ERC-12-0285
Chung, L. W. et al. Co-inoculation of tumorigenic rat prostate mesenchymal cells with non-tumorigenic epithelial cells results in the development of carcinosarcoma in syngeneic and athymic animals. Int. J. Cancer 43, 1179–1187 (1989).
pubmed: 2732007
doi: 10.1002/ijc.2910430636
Li, Y. et al. Decrease in stromal androgen receptor associates with androgen-independent disease and promotes prostate cancer cell proliferation and invasion. J. Cell Mol. Med. 12, 2790–2798 (2008).
pubmed: 18266956
pmcid: 3828892
doi: 10.1111/j.1582-4934.2008.00279.x
Craig, M., Ying, C. & Loberg, R. D. Co-inoculation of prostate cancer cells with U937 enhances tumor growth and angiogenesis in vivo. J. Cell Biochem. 103, 1–8 (2008).
pubmed: 17541941
doi: 10.1002/jcb.21379
Aigner, A. et al. Ribozyme-targeting of a secreted FGF-binding protein (FGF-BP) inhibits proliferation of prostate cancer cells in vitro and in vivo. Oncogene 21, 5733–5742 (2002).
pubmed: 12173043
doi: 10.1038/sj.onc.1205560
Klink, J. C. et al. Resveratrol worsens survival in SCID mice with prostate cancer xenografts in a cell-line specific manner, through paradoxical effects on oncogenic pathways. Prostate 73, 754–762 (2013).
pubmed: 23192356
doi: 10.1002/pros.22619
Chen, Q. H. Curcumin-based anti-prostate cancer agents. Anticancer. Agents Med. Chem. 15, 138–156 (2015).
pubmed: 25594891
doi: 10.2174/1871520615666150116102442
Jin, X. et al. DUB3 promotes BET inhibitor resistance and cancer progression by deubiquitinating BRD4. Mol. Cell 71, 592–605.e594 (2018).
pubmed: 30057199
pmcid: 6086352
doi: 10.1016/j.molcel.2018.06.036
Metzger, E. et al. KMT9 monomethylates histone H4 lysine 12 and controls proliferation of prostate cancer cells. Nat. Struct. Mol. Biol. 26, 361–371 (2019).
pubmed: 31061526
doi: 10.1038/s41594-019-0219-9
Voskoglou-Nomikos, T., Pater, J. L. & Seymour, L. Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. Clin. Cancer Res. 9, 4227–4239 (2003).
pubmed: 14519650
Yin, Z. et al. Current research developments of patient-derived tumour xenograft models (Review). Exp. Ther. Med. 22, 1206 (2021).
pubmed: 34584551
pmcid: 8422395
doi: 10.3892/etm.2021.10640
Xin, L., Ide, H., Kim, Y., Dubey, P. & Witte, O. N. In vivo regeneration of murine prostate from dissociated cell populations of postnatal epithelia and urogenital sinus mesenchyme. Proc. Natl Acad. Sci. USA 100, 11896–11903 (2003).
pubmed: 12909713
pmcid: 304104
doi: 10.1073/pnas.1734139100
Wang, Y. et al. An orthotopic metastatic prostate cancer model in SCID mice via grafting of a transplantable human prostate tumor line. Lab. Invest. 85, 1392–1404 (2005).
pubmed: 16155594
doi: 10.1038/labinvest.3700335
Liao, C. P., Adisetiyo, H., Liang, M. & Roy-Burman, P. Cancer-associated fibroblasts enhance the gland-forming capability of prostate cancer stem cells. Cancer Res. 70, 7294–7303 (2010).
pubmed: 20807814
pmcid: 2940948
doi: 10.1158/0008-5472.CAN-09-3982
Wang, X. et al. A luminal epithelial stem cell that is a cell of origin for prostate cancer. Nature 461, 495–500 (2009).
pubmed: 19741607
pmcid: 2800362
doi: 10.1038/nature08361
Stephenson, R. A. et al. Metastatic model for human prostate cancer using orthotopic implantation in nude mice. J. Natl Cancer Inst. 84, 951–957 (1992).
pubmed: 1378502
doi: 10.1093/jnci/84.12.951
Jäger, W. et al. Orthotopic mouse models of urothelial cancer. Methods Mol. Biol. 1655, 177–197 (2018).
pubmed: 28889387
doi: 10.1007/978-1-4939-7234-0_15
Singh, A. S. & Figg, W. D. In vivo models of prostate cancer metastasis to bone. J. Urol. 174, 820–826 (2005).
pubmed: 16093963
doi: 10.1097/01.ju.0000169133.82167.aa
Parajuli, K. R., Zhang, Q., Liu, S. & You, Z. Aminomethylphosphonic acid inhibits growth and metastasis of human prostate cancer in an orthotopic xenograft mouse model. Oncotarget 7, 10616–10626 (2016).
pubmed: 26840261
pmcid: 4891145
doi: 10.18632/oncotarget.7055
Hoffman, R. M. Orthotopic metastatic (MetaMouse) models for discovery and development of novel chemotherapy. Methods Mol. Med. 111, 297–322 (2005).
pubmed: 15911987
Xiang, Y. et al. SPARCL1 suppresses metastasis in prostate cancer. Mol. Oncol. 7, 1019–1030 (2013).
pubmed: 23916135
pmcid: 3838491
doi: 10.1016/j.molonc.2013.07.008
Thalmann, G. N. et al. Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res. 54, 2577–2581 (1994).
pubmed: 8168083
Pettaway, C. A. et al. Selection of highly metastatic variants of different human prostatic carcinomas using orthotopic implantation in nude mice. Clin. Cancer Res. 2, 1627–1636 (1996).
pubmed: 9816342
Patel, B. J. et al. CL1-GFP: an androgen independent metastatic tumor model for prostate cancer. J. Urol. 164, 1420–1425 (2000).
pubmed: 10992426
doi: 10.1016/S0022-5347(05)67210-2
Duan, Z. et al. Th17 cells promote tumor growth in an immunocompetent orthotopic mouse model of prostate cancer. Am. J. Clin. Exp. Urol. 7, 249–261 (2019).
pubmed: 31511831
pmcid: 6734037
Lardizabal, J., Ding, J., Delwar, Z., Rennie, P. S. & Jia, W. A TRAMP-derived orthotopic prostate syngeneic (TOPS) cancer model for investigating anti-tumor treatments. Prostate 78, 457–468 (2018).
pubmed: 29450905
doi: 10.1002/pros.23490
Anker, J. F., Mok, H., Naseem, A. F., Thumbikat, P. & Abdulkadir, S. A. A bioluminescent and fluorescent orthotopic syngeneic murine model of androgen-dependent and castration-resistant prostate cancer. J. Vis. Exp. https://doi.org/10.3791/57301 (2018).
doi: 10.3791/57301
pubmed: 29578515
pmcid: 5931443
Lange, T. et al. Development and characterization of a spontaneously metastatic patient-derived xenograft model of human prostate cancer. Sci. Rep. 8, 17535 (2018).
pubmed: 30510249
pmcid: 6277427
doi: 10.1038/s41598-018-35695-8
Shi, M., Wang, Y., Lin, D. & Wang, Y. Patient-derived xenograft models of neuroendocrine prostate cancer. Cancer Lett. 525, 160–169 (2022).
pubmed: 34767925
doi: 10.1016/j.canlet.2021.11.004
Rea, D. et al. Mouse models in prostate cancer translational research: from xenograft to PDX. Biomed. Res. Int. 2016, 9750795 (2016).
pubmed: 27294148
pmcid: 4887629
doi: 10.1155/2016/9750795
van Weerden, W. M. et al. Development of seven new human prostate tumor xenograft models and their histopathological characterization. Am. J. Pathol. 149, 1055–1062 (1996).
pubmed: 8780407
pmcid: 1865169
Palanisamy, N. et al. The MD Anderson prostate cancer patient-derived xenograft series (MDA PCa PDX) captures the molecular landscape of prostate cancer and facilitates marker-driven therapy development. Clin. Cancer Res. 26, 4933–4946 (2020).
pubmed: 32576626
pmcid: 7501166
doi: 10.1158/1078-0432.CCR-20-0479
Risbridger, G. P. et al. The MURAL collection of prostate cancer patient-derived xenografts enables discovery through preclinical models of uro-oncology. Nat. Commun. 12, 5049 (2021).
pubmed: 34413304
pmcid: 8376965
doi: 10.1038/s41467-021-25175-5
Evrard, Y. A. et al. Systematic establishment of robustness and standards in patient-derived xenograft experiments and analysis. Cancer Res. 80, 2286–2297 (2020).
pubmed: 32152150
pmcid: 7272270
doi: 10.1158/0008-5472.CAN-19-3101
Lin, D. et al. High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug development. Cancer Res. 74, 1272–1283 (2014).
pubmed: 24356420
doi: 10.1158/0008-5472.CAN-13-2921-T
Marques, R. B. et al. High efficacy of combination therapy using PI3K/AKT inhibitors with androgen deprivation in prostate cancer preclinical models. Eur. Urol. 67, 1177–1185 (2015).
pubmed: 25220373
doi: 10.1016/j.eururo.2014.08.053
Varkaris, A. et al. Integrating murine and clinical trials with cabozantinib to understand roles of MET and VEGFR2 as targets for growth inhibition of prostate cancer. Clin. Cancer Res. 22, 107–121 (2016).
pubmed: 26272062
doi: 10.1158/1078-0432.CCR-15-0235
Hammer, S. et al. Preclinical efficacy of a PSMA-targeted thorium-227 conjugate (PSMA-TTC), a targeted alpha therapy for prostate cancer. Clin. Cancer Res. 26, 1985–1996 (2020).
pubmed: 31831560
doi: 10.1158/1078-0432.CCR-19-2268
Ben-David, U. et al. Patient-derived xenografts undergo mouse-specific tumor evolution. Nat. Genet. 49, 1567–1575 (2017).
pubmed: 28991255
pmcid: 5659952
doi: 10.1038/ng.3967
Woo, X. Y. et al. Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts. Nat. Genet. 53, 86–99 (2021).
pubmed: 33414553
pmcid: 7808565
doi: 10.1038/s41588-020-00750-6
Verma, B., Ritchie, M. & Mancini, M. Development and applications of patient-derived xenograft models in humanized mice for oncology and immune-oncology drug discovery. Curr. Protoc. Pharmacol. 78, 14.41.11–14.41.12 (2017).
doi: 10.1002/cpph.26
Shultz, L. D., Brehm, M. A., Garcia-Martinez, J. V. & Greiner, D. L. Humanized mice for immune system investigation: progress, promise and challenges. Nat. Rev. Immunol. 12, 786–798 (2012).
pubmed: 23059428
pmcid: 3749872
doi: 10.1038/nri3311
Roth, M. D. & Harui, A. Human tumor infiltrating lymphocytes cooperatively regulate prostate tumor growth in a humanized mouse model. J. Immunother. Cancer 3, 12 (2015).
pubmed: 25901284
pmcid: 4404579
doi: 10.1186/s40425-015-0056-2
Valta, M. et al. Critical evaluation of the subcutaneous engraftments of hormone naïve primary prostate cancer. Transl. Androl. Urol. 9, 1120–1134 (2020).
pubmed: 32676396
pmcid: 7354344
doi: 10.21037/tau.2020.03.38
Liu, G. et al. Perturbation of NK cell peripheral homeostasis accelerates prostate carcinoma metastasis. J. Clin. Invest. 123, 4410–4422 (2013).
pubmed: 24018560
pmcid: 3784540
doi: 10.1172/JCI69369
Alix-Panabières, C. & Pantel, K. Liquid biopsy: from discovery to clinical application. Cancer Discov. 11, 858–873 (2021).
pubmed: 33811121
doi: 10.1158/2159-8290.CD-20-1311
Faugeroux, V. et al. Genetic characterization of a unique neuroendocrine transdifferentiation prostate circulating tumor cell-derived eXplant model. Nat. Commun. 11, 1884 (2020).
pubmed: 32313004
pmcid: 7171138
doi: 10.1038/s41467-020-15426-2
Keller, L. & Pantel, K. Unravelling tumour heterogeneity by single-cell profiling of circulating tumour cells. Nat. Rev. Cancer 19, 553–567 (2019).
pubmed: 31455893
doi: 10.1038/s41568-019-0180-2
Mout, L. et al. Generating human prostate cancer organoids from leukapheresis enriched circulating tumour cells. Eur. J. Cancer 150, 179–189 (2021).
pubmed: 33932725
doi: 10.1016/j.ejca.2021.03.023
Gunti, S., Hoke, A. T. K., Vu, K. P. & London, N. R. Jr Organoid and spheroid tumor models: techniques and applications. Cancers 13, 874 (2021).
pubmed: 33669619
pmcid: 7922036
doi: 10.3390/cancers13040874
Köcher, S. et al. A functional ex vivo assay to detect PARP1-EJ repair and radiosensitization by PARP-inhibitor in prostate cancer. Int. J. Cancer 144, 1685–1696 (2019).
pubmed: 30478958
doi: 10.1002/ijc.32018
Greenberg, N. M. et al. Prostate cancer in a transgenic mouse. Proc. Natl Acad. Sci. USA 92, 3439–3443 (1995).
pubmed: 7724580
pmcid: 42182
doi: 10.1073/pnas.92.8.3439
Ellwood-Yen, K. et al. Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell 4, 223–238 (2003).
pubmed: 14522256
doi: 10.1016/S1535-6108(03)00197-1
Freeman, K. W. et al. Inducible prostate intraepithelial neoplasia with reversible hyperplasia in conditional FGFR1-expressing mice. Cancer Res. 63, 8256–8263 (2003).
pubmed: 14678983
Hurwitz, A. A., Foster, B. A., Allison, J. P., Greenberg, N. M. & Kwon, E. D. The TRAMP mouse as a model for prostate cancer. Curr. Protoc. Immunol. https://doi.org/10.1002/0471142735.im2005s45 (2001).
doi: 10.1002/0471142735.im2005s45
pubmed: 18432778
Alajati, A. et al. CDCP1 overexpression drives prostate cancer progression and can be targeted in vivo. J. Clin. Invest. 130, 2435–2450 (2020).
pubmed: 32250342
pmcid: 7190998
doi: 10.1172/JCI131133
Jin, R. J. et al. The nuclear factor-κB pathway controls the progression of prostate cancer to androgen-independent growth. Cancer Res. 68, 6762–6769 (2008).
pubmed: 18701501
pmcid: 2840631
doi: 10.1158/0008-5472.CAN-08-0107
Wu, X. et al. Generation of a prostate epithelial cell-specific Cre transgenic mouse model for tissue-specific gene ablation. Mech. Dev. 101, 61–69 (2001).
pubmed: 11231059
doi: 10.1016/S0925-4773(00)00551-7
Kim, M. J. et al. Cooperativity of Nkx3.1 and Pten loss of function in a mouse model of prostate carcinogenesis. Proc. Natl Acad. Sci. USA 99, 2884–2889 (2002).
pubmed: 11854455
pmcid: 122442
doi: 10.1073/pnas.042688999
Wang, S. et al. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 4, 209–221 (2003).
pubmed: 14522255
doi: 10.1016/S1535-6108(03)00215-0
Mulholland, D. J. et al. Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth. Cancer Cell 19, 792–804 (2011).
pubmed: 21620777
pmcid: 3157296
doi: 10.1016/j.ccr.2011.05.006
Blattner, M. et al. SPOP mutation drives prostate tumorigenesis in vivo through coordinate regulation of PI3K/mTOR and AR signaling. Cancer Cell 31, 436–451 (2017).
pubmed: 28292441
pmcid: 5384998
doi: 10.1016/j.ccell.2017.02.004
Ding, Z. et al. Telomerase reactivation following telomere dysfunction yields murine prostate tumors with bone metastases. Cell 148, 896–907 (2012).
pubmed: 22341455
pmcid: 3629723
doi: 10.1016/j.cell.2012.01.039
Mulholland, D. J. et al. Pten loss and RAS/MAPK activation cooperate to promote EMT and metastasis initiated from prostate cancer stem/progenitor cells. Cancer Res. 72, 1878–1889 (2012).
pubmed: 22350410
pmcid: 3319847
doi: 10.1158/0008-5472.CAN-11-3132
Dardenne, E. et al. N-Myc induces an EZH2-mediated transcriptional program driving neuroendocrine prostate cancer. Cancer Cell 30, 563–577 (2016).
pubmed: 27728805
pmcid: 5540451
doi: 10.1016/j.ccell.2016.09.005
Ding, Z. et al. SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature 470, 269–273 (2011).
pubmed: 21289624
pmcid: 3753179
doi: 10.1038/nature09677
Zhao, D. et al. Chromatin regulator CHD1 remodels the immunosuppressive tumor microenvironment in PTEN-deficient prostate cancer. Cancer Discov. 10, 1374–1387 (2020).
pubmed: 32385075
pmcid: 7483306
doi: 10.1158/2159-8290.CD-19-1352
Lu, X. et al. Effective combinatorial immunotherapy for castration-resistant prostate cancer. Nature 543, 728–732 (2017).
pubmed: 28321130
pmcid: 5374023
doi: 10.1038/nature21676
Taavitsainen, S. et al. Single-cell ATAC and RNA sequencing reveal pre-existing and persistent cells associated with prostate cancer relapse. Nat. Commun. 12, 5307 (2021).
pubmed: 34489465
pmcid: 8421417
doi: 10.1038/s41467-021-25624-1
Brady, L. et al. Inter- and intra-tumor heterogeneity of metastatic prostate cancer determined by digital spatial gene expression profiling. Nat. Commun. 12, 1426 (2021).
pubmed: 33658518
pmcid: 7930198
doi: 10.1038/s41467-021-21615-4
Zhao, T. et al. Spatial genomics enables multi-modal study of clonal heterogeneity in tissues. Nature 601, 85–91 (2022).
pubmed: 34912115
doi: 10.1038/s41586-021-04217-4
Chelebian, E. et al. Morphological features extracted by AI associated with spatial transcriptomics in prostate cancer. Cancers 13, 4837 (2021).
pubmed: 34638322
pmcid: 8507756
doi: 10.3390/cancers13194837
Haffner, M. C. et al. Genomic and phenotypic heterogeneity in prostate cancer. Nat. Rev. Urol. 18, 79–92 (2021).
pubmed: 33328650
doi: 10.1038/s41585-020-00400-w
Hong, M. K. et al. Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer. Nat. Commun. 6, 6605 (2015).
pubmed: 25827447
doi: 10.1038/ncomms7605
Gundem, G. et al. The evolutionary history of lethal metastatic prostate cancer. Nature 520, 353–357 (2015).
pubmed: 25830880
pmcid: 4413032
doi: 10.1038/nature14347
van de Wetering, M. et al. Prospective derivation of a living organoid biobank of colorectal cancer patients. Cell 161, 933–945 (2015).
pubmed: 25957691
pmcid: 6428276
doi: 10.1016/j.cell.2015.03.053
Cao, J., Chan, W. C. & Chow, M. S. S. Use of conditional reprogramming cell, patient derived xenograft and organoid for drug screening for individualized prostate cancer therapy: current and future perspectives (Review). Int. J. Oncol. 60, 52 (2022).
pubmed: 35322860
doi: 10.3892/ijo.2022.5342
Heidegger, I. et al. Comprehensive characterization of the prostate tumor microenvironment identifies CXCR4/CXCL12 crosstalk as a novel antiangiogenic therapeutic target in prostate cancer. Mol. Cancer 21, 132 (2022).
pubmed: 35717322
pmcid: 9206324
doi: 10.1186/s12943-022-01597-7
Zhang, Z. et al. Tumor microenvironment-derived NRG1 promotes antiandrogen resistance in prostate cancer. Cancer Cell 38, 279–296.e279 (2020).
pubmed: 32679108
pmcid: 7472556
doi: 10.1016/j.ccell.2020.06.005
Javier-DesLoges, J. et al. The microbiome and prostate cancer. Prostate Cancer Prostatic Dis. 25, 159–174 (2021).
pubmed: 34267333
pmcid: 8767983
doi: 10.1038/s41391-021-00413-5
Poore, G. D. et al. Microbiome analyses of blood and tissues suggest cancer diagnostic approach. Nature 579, 567–574 (2020).
pubmed: 32214244
pmcid: 7500457
doi: 10.1038/s41586-020-2095-1
Daisley, B. A. et al. Abiraterone acetate preferentially enriches for the gut commensal Akkermansia muciniphila in castrate-resistant prostate cancer patients. Nat. Commun. 11, 4822 (2020).
pubmed: 32973149
pmcid: 7515896
doi: 10.1038/s41467-020-18649-5
Pernigoni, N. et al. Commensal bacteria promote endocrine resistance in prostate cancer through androgen biosynthesis. Science 374, 216–224 (2021).
pubmed: 34618582
doi: 10.1126/science.abf8403
Terrisse, S. et al. Immune system and intestinal microbiota determine efficacy of androgen deprivation therapy against prostate cancer. J. Immunother. Cancer 10, e004191 (2022).
pubmed: 35296557
pmcid: 8928383
doi: 10.1136/jitc-2021-004191
Meijer, T. G., Naipal, K. A., Jager, A. & van Gent, D. C. Ex vivo tumor culture systems for functional drug testing and therapy response prediction. Future Sci. OA 3, FSO190 (2017).
pubmed: 28670477
pmcid: 5481868
doi: 10.4155/fsoa-2017-0003
Contreras-Trujillo, H. et al. Deciphering intratumoral heterogeneity using integrated clonal tracking and single-cell transcriptome analyses. Nat. Commun. 12, 6522 (2021).
pubmed: 34764253
pmcid: 8586369
doi: 10.1038/s41467-021-26771-1
von Amsberg, G. et al. Immunotherapy in advanced prostate cancer-light at the end of the tunnel? Int. J. Mol. Sci. 23, 2569 (2022).
doi: 10.3390/ijms23052569
Goldenberg, S. L., Nir, G. & Salcudean, S. E. A new era: artificial intelligence and machine learning in prostate cancer. Nat. Rev. Urol. 16, 391–403 (2019).
pubmed: 31092914
doi: 10.1038/s41585-019-0193-3
Kann, B. H., Hosny, A. & Aerts, H. Artificial intelligence for clinical oncology. Cancer Cell 39, 916–927 (2021).
pubmed: 33930310
pmcid: 8282694
doi: 10.1016/j.ccell.2021.04.002
Gupta, R. et al. Artificial intelligence to deep learning: machine intelligence approach for drug discovery. Mol. Divers. 25, 1315–1360 (2021).
pubmed: 33844136
pmcid: 8040371
doi: 10.1007/s11030-021-10217-3
Mickey, D. D., Stone, K. R., Stone, M. P. & Paulson, D. F. Morphologic and immunologic studies of human prostatic carcinoma. Cancer Treat. Rep. 61, 133–138 (1977).
pubmed: 68819
Williams, R. D. et al. Biochemical markers of cultured human prostatic epithelium. J. Urol. 119, 768–771 (1978).
pubmed: 660762
doi: 10.1016/S0022-5347(17)57628-4
Williams, R. D. Human urologic cancer cell lines. Invest. Urol. 17, 359–363 (1980).
pubmed: 6244232
Horoszewicz, J. S. et al. LNCaP model of human prostatic carcinoma. Cancer Res. 43, 1809–1818 (1983).
pubmed: 6831420
Claas, F. H. & van Steenbrugge, G. J. Expression of HLA-like structures on a permanent human tumor line PC-93. Tissue Antigens 21, 227–232 (1983).
pubmed: 6602397
doi: 10.1111/j.1399-0039.1983.tb00162.x
Romijn, J. C., Verkoelen, C. F. & Schroeder, F. H. Application of the MTT assay to human prostate cancer cell lines in vitro: establishment of test conditions and assessment of hormone-stimulated growth and drug-induced cytostatic and cytotoxic effects. Prostate 12, 99–110 (1988).
pubmed: 3126493
doi: 10.1002/pros.2990120112
Carney, D. N. et al. Establishment and identification of small cell lung cancer cell lines having classic and variant features. Cancer Res. 45, 2913–2923 (1985).
pubmed: 2985257
Johnson, B. E. et al. Retention of chromosome 3 in extrapulmonary small cell cancer shown by molecular and cytogenetic studies. J. Natl Cancer Inst. 81, 1223–1228 (1989).
pubmed: 2569043
doi: 10.1093/jnci/81.16.1223
Gingrich, J. R. et al. Establishment and characterization of a new human prostatic carcinoma cell line (DuPro-1). J. Urol. 146, 915–919 (1991).
pubmed: 1875519
doi: 10.1016/S0022-5347(17)37960-0
Plymate, S. R. et al. Effects of sex hormone binding globulin (SHBG) on human prostatic carcinoma. J. Steroid Biochem. Mol. Biol. 40, 833–839 (1991).
pubmed: 1958578
doi: 10.1016/0960-0760(91)90309-S
Mehta, P. P. et al. Gap-junctional communication in normal and neoplastic prostate epithelial cells and its regulation by cAMP. Mol. Carcinog. 15, 18–32 (1996).
pubmed: 8561862
doi: 10.1002/(SICI)1098-2744(199601)15:1<18::AID-MC4>3.0.CO;2-O
Marques, R. B. et al. Androgen receptor modifications in prostate cancer cells upon long-term androgen ablation and antiandrogen treatment. Int. J. Cancer 117, 221–229 (2005).
pubmed: 15900601
doi: 10.1002/ijc.21201
Zhau, H. Y. et al. Androgen-repressed phenotype in human prostate cancer. Proc. Natl Acad. Sci. USA 93, 15152–15157 (1996).
pubmed: 8986779
pmcid: 26372
doi: 10.1073/pnas.93.26.15152
Klein, K. A. et al. Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice. Nat. Med. 3, 402–408 (1997).
pubmed: 9095173
doi: 10.1038/nm0497-402
Navone, N. M. et al. Establishment of two human prostate cancer cell lines derived from a single bone metastasis. Clin. Cancer Res. 3, 2493–2500 (1997).
pubmed: 9815652
Navone, N. M. et al. TabBO: a model reflecting common molecular features of androgen-independent prostate cancer. Clin. Cancer Res. 6, 1190–1197 (2000).
pubmed: 10741751
Pretlow, T. G. et al. Xenografts of primary human prostatic carcinoma. J. Natl Cancer Inst. 85, 394–398 (1993).
pubmed: 8433392
doi: 10.1093/jnci/85.5.394
Wainstein, M. A. et al. CWR22: androgen-dependent xenograft model derived from a primary human prostatic carcinoma. Cancer Res. 54, 6049–6052 (1994).
pubmed: 7525052
Sramkoski, R. M. et al. A new human prostate carcinoma cell line, 22Rv1. Vitr. Cell Dev. Biol. Anim. 35, 403–409 (1999).
doi: 10.1007/s11626-999-0115-4
Gregory, C. W., Johnson, R. T. Jr, Mohler, J. L., French, F. S. & Wilson, E. M. Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res. 61, 2892–2898 (2001).
pubmed: 11306464
Wu, H. C. et al. Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: role of bone stromal cells. Int. J. Cancer 57, 406–412 (1994).
pubmed: 8169003
doi: 10.1002/ijc.2910570319
Loop, S. M., Rozanski, T. A. & Ostenson, R. C. Human primary prostate tumor cell line, ALVA-31: a new model for studying the hormonal regulation of prostate tumor cell growth. Prostate 22, 93–108 (1993).
pubmed: 7681207
doi: 10.1002/pros.2990220202
Nakhla, A. M. & Rosner, W. Characterization of ALVA-41 cells, a new human prostatic cancer cell line. Steroids 59, 586–589 (1994).
pubmed: 7533340
doi: 10.1016/0039-128X(94)90052-3
Brothman, A. R., Lesho, L. J., Somers, K. D., Wright, G. L. Jr & Merchant, D. J. Phenotypic and cytogenetic characterization of a cell line derived from primary prostatic carcinoma. Int. J. Cancer 44, 898–903 (1989).
pubmed: 2583869
doi: 10.1002/ijc.2910440525
Bae, V. L., Jackson-Cook, C. K., Brothman, A. R., Maygarden, S. J. & Ware, J. L. Tumorigenicity of SV40 T antigen immortalized human prostate epithelial cells: association with decreased epidermal growth factor receptor (EGFR) expression. Int. J. Cancer 58, 721–729 (1994).
pubmed: 8077059
doi: 10.1002/ijc.2910580517
Bello, D., Webber, M. M., Kleinman, H. K., Wartinger, D. D. & Rhim, J. S. Androgen responsive adult human prostatic epithelial cell lines immortalized by human papillomavirus 18. Carcinogenesis 18, 1215–1223 (1997).
pubmed: 9214605
doi: 10.1093/carcin/18.6.1215
Rhim, J. S. et al. Stepwise immortalization and transformation of adult human prostate epithelial cells by a combination of HPV-18 and v-Ki-ras. Proc. Natl Acad. Sci. USA 91, 11874–11878 (1994).
pubmed: 7991549
pmcid: 45338
doi: 10.1073/pnas.91.25.11874
Webber, M. M. et al. Prostate specific antigen and androgen receptor induction and characterization of an immortalized adult human prostatic epithelial cell line. Carcinogenesis 17, 1641–1646 (1996).
pubmed: 8761420
doi: 10.1093/carcin/17.8.1641
Webber, M. M. et al. A human prostatic stromal myofibroblast cell line WPMY-1: a model for stromal-epithelial interactions in prostatic neoplasia. Carcinogenesis 20, 1185–1192 (1999).
pubmed: 10383888
doi: 10.1093/carcin/20.7.1185
Koochekpour, S. et al. Establishment and characterization of a primary androgen-responsive African-American prostate cancer cell line, E006AA. Prostate 60, 141–152 (2004).
pubmed: 15162380
doi: 10.1002/pros.20053
Ke, X. S. et al. Epithelial to mesenchymal transition of a primary prostate cell line with switches of cell adhesion modules but without malignant transformation. PLoS ONE 3, e3368 (2008).
pubmed: 18852876
pmcid: 2557125
doi: 10.1371/journal.pone.0003368
Theodore, S. et al. Establishment and characterization of a pair of non-malignant and malignant tumor derived cell lines from an African American prostate cancer patient. Int. J. Oncol. 37, 1477–1482 (2010).
pubmed: 21042716
Szczyrba, J. et al. The microRNA profile of prostate carcinoma obtained by deep sequencing. Mol. Cancer Res. 8, 529–538 (2010).
pubmed: 20353999
doi: 10.1158/1541-7786.MCR-09-0443
Acevedo, V. D. et al. Inducible FGFR-1 activation leads to irreversible prostate adenocarcinoma and an epithelial-to-mesenchymal transition. Cancer Cell 12, 559–571 (2007).
pubmed: 18068632
doi: 10.1016/j.ccr.2007.11.004
Bhatia-Gaur, R. et al. Roles for Nkx3.1 in prostate development and cancer. Genes Dev. 13, 966–977 (1999).
pubmed: 10215624
pmcid: 316645
doi: 10.1101/gad.13.8.966
Wan, X. et al. Prostate cancer cell-stromal cell crosstalk via FGFR1 mediates antitumor activity of dovitinib in bone metastases. Sci. Transl. Med. 6, 252ra122 (2014).
pubmed: 25186177
pmcid: 4407499
doi: 10.1126/scitranslmed.3009332
Pecqueux, C. et al. FGF-2 is a driving force for chromosomal instability and a stromal factor associated with adverse clinico-pathological features in prostate cancer. Urol. Oncol. 36, 365.e315–365.e326 (2018).
doi: 10.1016/j.urolonc.2018.05.020
Wach, S. et al. MicroRNA profiles of prostate carcinoma detected by multiplatform microRNA screening. Int. J. Cancer 130, 611–621 (2012).
pubmed: 21400514
doi: 10.1002/ijc.26064
Wach, S. et al. Exploring the MIR143-UPAR axis for the inhibition of human prostate cancer cells in vitro and in vivo. Mol. Ther. Nucleic Acids 16, 272–283 (2019).
pubmed: 30933831
pmcid: 6444223
doi: 10.1016/j.omtn.2019.02.020
McClurg, U. L. et al. Human ex vivo prostate tissue model system identifies ING3 as an oncoprotein. Br. J. Cancer 118, 713–726 (2018).
pubmed: 29381681
pmcid: 5846061
doi: 10.1038/bjc.2017.447
Ewe, A. et al. Optimized polyethylenimine (PEI)-based nanoparticles for siRNA delivery, analyzed in vitro and in an ex vivo tumor tissue slice culture model. Drug Deliv. Transl. Res. 7, 206–216 (2017).
pubmed: 27334279
doi: 10.1007/s13346-016-0306-y
Karimov, M., Appelhans, D., Ewe, A. & Aigner, A. The combined disulfide cross-linking and tyrosine-modification of very low molecular weight linear PEI synergistically enhances transfection efficacies and improves biocompatibility. Eur. J. Pharm. Biopharm. 161, 56–65 (2021).
pubmed: 33582186
doi: 10.1016/j.ejpb.2021.02.005
Hu, R. et al. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res. 69, 16–22 (2009).
pubmed: 19117982
pmcid: 2614301
doi: 10.1158/0008-5472.CAN-08-2764
Antonarakis, E. S. et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N. Engl. J. Med. 371, 1028–1038 (2014).
pubmed: 25184630
pmcid: 4201502
doi: 10.1056/NEJMoa1315815
Scher, H. I. et al. Association of AR-V7 on circulating tumor cells as a treatment-specific biomarker with outcomes and survival in castration-resistant prostate cancer. JAMA Oncol. 2, 1441–1449 (2016).
pubmed: 27262168
pmcid: 5206761
doi: 10.1001/jamaoncol.2016.1828
Armstrong, A. J. et al. Prospective multicenter validation of androgen receptor splice variant 7 and hormone therapy resistance in high-risk castration-resistant prostate cancer: the PROPHECY study. J. Clin. Oncol. 37, 1120–1129 (2019).
pubmed: 30865549
pmcid: 6494355
doi: 10.1200/JCO.18.01731
Bernemann, C. et al. Expression of AR-V7 in circulating tumour cells does not preclude response to next generation androgen deprivation therapy in patients with castration resistant prostate cancer. Eur. Urol. 71, 1–3 (2017).
pubmed: 27471164
doi: 10.1016/j.eururo.2016.07.021
Bernemann, C., Krabbe, L. M. & Schrader, A. J. Considerations for AR-V7 testing in clinical routine practice. Ann. Transl. Med. 7, S378 (2019).
pubmed: 32016096
pmcid: 6976390
doi: 10.21037/atm.2019.12.136
Del Re, M. et al. The detection of androgen receptor splice variant 7 in plasma-derived exosomal RNA strongly predicts resistance to hormonal therapy in metastatic prostate cancer patients. Eur. Urol. 71, 680–687 (2017).
pubmed: 27733296
doi: 10.1016/j.eururo.2016.08.012
Del Re, M. et al. Androgen receptor gain in circulating free DNA and splicing variant 7 in exosomes predict clinical outcome in CRPC patients treated with abiraterone and enzalutamide. Prostate Cancer Prostatic Dis. 24, 524–531 (2021).
pubmed: 33500577
pmcid: 8134038
doi: 10.1038/s41391-020-00309-w
Lieb, V. et al. Cell-free DNA variant sequencing using plasma and AR-V7 testing of circulating tumor cells in prostate cancer patients. Cells 10, 3223 (2021).
pubmed: 34831445
pmcid: 8620951
doi: 10.3390/cells10113223
Li, Q. et al. Clinicopathological characteristics of androgen receptor splicing variant 7 (AR-V7) expression in patients with castration resistant prostate cancer: a systematic review and meta-analysis. Transl. Oncol. 14, 101145 (2021).
pubmed: 34130051
pmcid: 8214144
doi: 10.1016/j.tranon.2021.101145
Brown, L. C., Lu, C., Antonarakis, E. S., Luo, J. & Armstrong, A. J. Androgen receptor variant-driven prostate cancer II: advances in clinical investigation. Prostate Cancer Prostatic Dis. 23, 367–380 (2020).
pubmed: 32094489
doi: 10.1038/s41391-020-0215-5